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ADAM A Disintegrin and Metalloprotease 
BB-94 Batimastat 
BSA Bovine serum albumin 
°C  Celsius 
CD  Cytoplasmic domain 
CO2  Carbon dioxide 
CT1746 (N1-[2-(S)-(3,3-dimethylbutanamidyl)]-N4-hydroxy-2-(R)-[3-(4-chlo
rophenyl)-propyl] succinamide 
Cys cysteine-rich domain 
DIS  Disintegrin domain 
DMSO   Dimethylsulfoxide 
DMEM  Dulbecco's modified eagle medium 
FN Fibronectin 
FBS  Fetal bovine serum 
h hour 
hEctoA8 human EctoADAM8 
kDa  Kilo Dalton 
MP metalloprotease domain 
min  Minute 
ml  Milliliter 
NaCl  Sodium chloride 
PFA Paraformaldehyde 
PBS  Phosphate buffered saline 
Pro prodomain 
SDS  Sodium dodecylsulphate 
SDS-PAGE  SDS-Polyacrylamide gel electrophoresis 
TEMED  N,N,N',N'-Tetramethylethylenediamine 
Tris  Tris-(hydroxy methyl)-amino methane 
TM  Transmembrane domain 
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1. Introduction 
 
1.1 A Disintegrin and Metalloprotease (ADAM) family member-ADAM8 
ADAM8 (also known as CD156a, MS2) was originally cloned from a murine 
macrophage cDNA library and described as a novel cell surface protein mainly 
expressed on monocytes
1
. ADAM8 has the typical structure of an ADAM family 
member consisting of an inhibitory prodomain (Pro), a metalloprotease domain (MP), 
a disintegrin domain (DIS), a cysteine-rich domain (Cys), a EGF-like domain (EGF) 
followed by the transmembrane (TM) and the cytoplasmic domain (CD)
2
.
  
 
 
 
 
 
Figure 1: Domain organisation of ADAM8 
Protein domains are drawn to scale, and the amino acid positions are given below. Abbreviations for domains: Pro, 
prodomain; MP, metalloprotease; DIS, disintegrin; CR, cysteine-rich; EGF, EGF-like domain; TM, transmembrane 
domain; CD, cytoplasmic domain. The extracellular ectodomain of ADAM8 (EctoA8) consists of CR, DIS and MP 
with or without Pro. Scheme adapted from Koller et al2. 
 
ADAM8 is produced as an inactive pro-protein (pro-ADAM8). The mature active 
form is activated by removal of the prodomain. In contrast to most other 
proteolytically active ADAMs, ADAM8 contains a non-canonical furin consensus 
sequence (RETR as opposed to RX (K/R) R) in the hinge region between the Pro and 
MP domain. Instead of furin-mediated cleavage, the Pro domain is removed by an 
autocatalytic mechanism
3
. In addition to its proteolytic activity, ADAM8 DIS domain 
contains an integrin binding loop with a central KDM motif as opposed to an integrin 
binding RGD motif present in the analogous position of human ADAM15. It was 
shown that the recombinant DIS/Cys/EGF (DCE) domain of ADAM8 mediates cell 
adhesion with ADAM8-expressing cells
3
.
 
ADAM8 was originally described in relation to its involvement in inflammatory 
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processes
4
 and subsequently in many systems of the body
2
. Recently, additional work 
demonstrated a role of ADAM8 in tumors, in particular in adenocarcinomas. In 
pancreatic ductal adenocarcinoma (PDAC) patient samples, high ADAM8 expression 
levels have been associated with a poor patient prognosis with regard to survival and 
metastatic spread
5
. This correlation was also observed in high-grade glioma
6
, lung 
adenocarcinoma
7
, prostate cancer
8 
and more recently in squamous head and neck cell 
carcinoma
9
, medulloblastoma
10
 and osteosarcoma
11 
suggesting that ADAM8 plays an 
active role in tumor progression, underlining the need to understand the functional 
role of ADAM8 in tumor biology. Up to now, ADAM8 has been associated with 
increased tumor cell migration, invasion and metastasis via a combination of catalytic, 
adhesion and cell signaling functions
5, 6
. From a very recent study it is clear that 
ADAM8 interacts with integrin β1 on the cell surface and activates intracellular 
signaling via p-ERK1/2 and PI3K and Akt signaling
12
. 
Recombinant ADAM8 has catalytic activity towards a number of peptide 
substrates
13-16
.
 
From these peptide sequences, cleavage in vivo was demonstrated for 
five substrates: Amyloid Precursor protein, APP 
14
; low affinity IgE receptor, CD23 
15
; 
L-selectin
17
; tumor necrosis factor alpha receptor 1, TNF-R1
18
 and P-Selectin 
Glycoprotein Ligand-1 (PSGL-1)
19
. In particular, for TNF-R1, the findings 
demonstrate an additional neuroprotective role for ADAM8 under neurodegeneration 
conditions via TNF-R1 shedding: Adam8 deficiency in mice with motoneuron 
degeneration (MND) (Adam8
-/-
 wr/wr) showed an aggravated disease phenotype with 
survival, earlier onset, even more dramatic motor neuron loss in the spinal cord and 
increased reactive gliosis. Under neurodegenerative conditions in MND mice, TNF-α 
is activated in neurons, astrocytes and microglia and induces apoptosis via the 
TNF-R1 pathway. Shedding of TNF-R1 by ADAM8 produces the soluble form of 
TNF-R1, which binds TNF-α, thus desensitising cells to its apoptotic action. It was 
shown that TNF-R1 shedding was completely abolished in Adam8
-/-
 wr/wr mice thus 
negatively affecting neuronal survival. From this study it was concluded that ADAM8 
is an inflammation-induced ‘sheddase’ for TNF-R1 with neuroprotective effects in 
CNS pathology
18
.
 
More recent work demonstrates an important role for ADAM8 in 
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elimination of injured muscle fibers prior to skeletal muscle regeneration: Skeletal 
muscle of dystrophin-null mice, an animal model for Duchenne Muscular Dystrophy, 
deteriorates by the lack of ADAM8, which is characterized by increased area of 
muscle degeneration and increased number of necrotic and calcified muscle fibers. 
ADAM8 is highly expressed in neutrophils. Upon cardiotoxin-induced skeletal 
muscle injury, neutrophils invade into muscle fibers through the basement membrane 
and form large clusters in wild type, but not in Adam8
-/-
 mice, although neutrophils of 
latter infiltrate into interstitial tissues similarly to those of wild type mice, whereas 
expression of PSGL-1 on the surface of neutrophils remains higher in Adam8
-/-
 than in 
wild-type mice. Thus, ADAM8-dependent ectodomain shedding of PSGL-1 could 
contribute to the removal of cell surface PSGL-1 of neutrophils after their 
infiltration
19
. 
In order to characterise ADAM8 function in vitro, a soluble ectodomain lacking the 
transmembrane and the cytoplasmic domains should be produced. This human 
EctoADAM8 (hEctoA8) protein consists of the prodomain, metalloprotease domain 
(MP), a disintegrin domain (DIS), a cysteine-rich domain (Cys) and a EGF-like 
domain (EGF), whilst removal of the prodomain by autocatalysis leads to the active 
form of hEctoA8
3
. Like the full-length ADAM8, hEctoA8 contains the catalytic 
consensus sequence HEXXHXXGXXHD in the metalloprotease domain and is 
therefore predicted to be proteolytically active
20
. Up to now, functional studies on 
ADAM8 in vitro were hampered by the lack of sufficient quantities of folded, 
biologically active, and purified recombinant forms of hEctoA8. 
Thus, in the study presented here, we propose to express and purify the recombinant 
ectodomain of human ADAM8 (hEctoA8) protein from supernatants of transfected 
HEK cells and investigate the biological properties of ADAM8 with respect to 
substrates, cell adhesion and signaling. 
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1.2 CD23 
CD23 was one of the first described substrates for ADAM8 with implications for 
inflammatory and allergic disease. CD23, also known as Fc epsilon RII, or FcεRII, is 
the "low-affinity" receptor for IgE, an antibody isotype involved in allergy and 
resistance to parasites, and is important in regulation of cellular IgE levels. Unlike 
many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells, 
activated macrophages, eosinophils, follicular dendritic cells, and platelets. 
Two isoforms of CD23 exist which are CD23a and CD23b. Whereas CD23a is present 
on follicular B cells, CD23b requires IL-4 to be expressed on T-cells, monocytes, 
langerhans cells, eosinophils, and macrophages
21
. CD23 is known to have a role in 
mediating antibody feedback regulation. Antigen that enters the blood stream is 
captured by antigen specific IgE antibodies. The IgE immune complexes that are 
formed bind to CD23 molecules on B cells, and are transported to the B cell follicles 
of the spleen. The antigen is then transferred from CD23+ B cells to CD11c+ antigen 
presenting cells. The CD11c+ cells in turn present the antigen to CD4+ T cells, which 
can lead to an enhanced antibody response
22
. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schematic representation of human CD23  
Two isoforms have been described for human CD23 which differ only in the N-terminal sequence. Some important 
structural features indicated are the leucine-zipper, mediating formation of homotrimers, the C-type lectin domain, 
with the ability to bind either the IgE-protein portion or carbohydrate chains containing a terminal galactose, the 
protease cleavage sites giving rise to sCD23 molecules of the indicated fragment sizes, and an inverse RGD 
sequence. RGD sequences have a function in the interaction of integrins with their ligands23. 
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CD23 is cleaved from the cell surface to generate a number of soluble forms that have 
been shown to be elevated in a number of diseases such as asthma, rheumatoid 
arthritis, and inflammatory bowel disease
24
. Soluble forms of CD23 play an important 
role in the up-regulation of IgE synthesis by interaction with B cells
25
, as well as 
promoting the induction of inflammatory cytokines by macrophage
24
. ADAM8 can 
contribute to shedding of CD23 to form soluble CD23
15
, though shedding was not 
reduced in ADAM8 deficient mice 
26
 demonstrating that ADAM8 is not a constitutive 
shedding enzyme for CD23, a role assigned to ADAM10. It seems plausible that 
ADAM8 is amplifying the shedding of allergy-related molecules only under 
pro-inflammatory conditions. In this respect, ADAM10 is not significantly 
upregulated in its expression by neither LPS nor TNF-α26. Based on the observed 
shedding of CD23 from the cell surface, a fluorogenic substrate containing the exact 
CD23 cleavage sequence Dabcyl-His-Gly-Asp-Gln-Met-Ala-Gln-Lys-Ser-Lys 
(5-Fam)-NH2) could be designed to detect ADAM8 activity in in vitro assays. 
Due to this activity towards CD23, it can be postulated that soluble ADAM8 could 
cleave CD23 from the cell surface in trans, i.e. on the adjacent cell. A large amount of 
recombinant soluble ADAM8 would allow to address this question.  
 
1.3 Fibronectin (FN)   
Another described substrate of ADAM8 is Fibronectin (FN). FN is a high-molecular 
weight (~440kDa) glycoprotein of the extracellular matrix (ECM) that binds to 
membrane-spanning receptor proteins called integrins
27
. Similar to integrins, FN 
binds extracellular matrix components such as collagen, fibrin, and heparan sulfate 
proteoglycans. FN exists as a protein dimer, consisting of two nearly identical 
monomers linked by a pair of disulfide bonds
27
. The FN protein is produced from a 
single gene, but alternative splicing of its pre-mRNA leads to several isoforms. 
FN plays a major role in cell adhesion, growth, migration, and differentiation, and it is 
important for processes such as wound healing and embryonic development
27
. Altered 
FN expression, degradation, and organisation are associated with a number of 
pathologies, including cancer and fibrosis
28
. 
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Figure 3: Diagram of dimeric fibronectin 
The disulfide bonded nearly identical polypeptide chains consist of homologous type I (circles), II (hexagons), and 
III (squares) repeats. The RGD containing cell binding domain (CBD) and the HepII domain are indicated by 
shaded squares. Alternatively spliced exons (EDA, EDB, and V) contribute to the various isoforms of fibronectin. 
Exon subdivision of the V exon is indicated in the box29. 
 
Besides shedding of membrane proteins, ADAM8 cleaves molecules of the ECM. As 
reported for experimental autoimmune arthritis (EAA), a condition associated with 
enhanced cleavage of ECM molecules, ADAM8 inactivation by introducing the 
E330Q mutant into an ADAM8 deficient background in mice resulted in a milder 
disease progression of EAA
30
, later shown to be associated with reduced cleavage of 
FN at the Ala271 redidue
31
. A recent study has identified FN fragments of 25- to 
29-kDa in degenerative human intevertebral discs (IVD)
32
, and data supporting a 
pathophysiological role of FN-fragments are emerging: the 29-kDa N-terminal 
FN-fragment is capable of causing disc degeneration in rabbits
33
.
 
ADAM8 was 
identified in degenerative IVD tissues and could play an important role in FN 
fragmentation associated with disc tissue degeneration
32
.  
In the present study, we will investigate cleavage of FN in vitro using recombinant 
hEctoA8 and FN together for 48 h in 37
o
C water bath and analyse recombinant 
hEctoA8 cleavage of FN on tumor cell adhesion and signal transduction. 
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1.4 Inhibitor of ADAM8  
Batimastat, BB-94 (molecular formula: C23H31N3O4S2) is a well-known synthetic 
inhibitor of metalloproteases containing a peptide domain mimicking the cleavage site 
of collagen and a hydroxamate group, which is bound by metalloproteases and blocks 
the zinc ion in the catalytic site of the metalloprotease, respectively. The 
metalloprotease is thereby inactivated. Since the majority of MPs share a homologous 
catalytic domain, BB-94 exhibits a broad-spectrum inhibition property
34
. 
 
 
 
 
 
 
Figure 4: X-ray structure of the ADAM8 MP domain in complex with hydroxamate inhibitor BB-94. 
Left: Secondary structure model with BB-94 shown in the catalytic site. Right: Detailed view of BB-94 
complexing the Zn ion in the catalytic center by two oxygens (red) from BB-94. 
 
In our study, we would use BB-94 to inhibit catalytic activity of recombinant hEctoA8 
and investigate the change of its biological properties; we also would pursue to 
identify novel and more specific inhibitors by comparing their potency to BB-94. 
Aims of this study 
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2. Aims of this study 
 
 Expression and purification of recombinant hEctoA8 protein from 
supernatants of transfected HEK cells;  
 Analysis of cleavage properties of recombinant hEctoA8 with substrates CD23 
in trans and FN in vitro; 
 Effect of recombinant hEctoA8 cleavage of FN on tumor cell adhesion and 
intracellular signaling.  
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3. Materials 
 
3.1 Cell lines 
A stable HEK cell line expressing recombinant hEctoA8 and a CD23 stably 
transfected Panc1 cell lines were generated by Uwe Schlomann; Pancreatic tumor 
(Panc1_WT) cells were obtained from Sigma UK; In addition, an ADAM8 
overexpressing Panc1 cell line (Panc1_A8) was also generated by Uwe Schlomann as 
described
12
.  
   
3.2 Media and solutions for cell culture 
HEK-293 cells and Panc1 cells were cultured in DMEM (Dulbecco’s Modified Eagle 
Medium) High Glucose (4.5 g/l) supplemented with 1% L-Glutamine (200 mM), 1% 
Penicillin/ Streptomycin 100×, 1 mM sodium pyruvate solution, 1% MEM Non 
Essential Amino Acids 100× and 10% Fetal Bovine Serum (heat inactivated). 
 
For purification of recombinant hEctoA8 from supernatant, complete growth medium 
was exchanged by DMEM High Glucose (4.5 g/l) without serum and phenol red on 
the days before collecting the supernatant and harvesting the cells. 
 
All materials above were bought from PAA Laboratories GmbH. 
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3.3 Kits 
Description Manufacturer 
HisTALON
TM
 Buffer Set 
Clontech 
TAKARA 
BIOTECHNOLOGY(DALAN)CO.LTD 
Pierce® Silver Stain Kit  
Thermo Scientific 
 Rockford USA 
4%-20% Precast Gel 
Expedeon 
San Diego USA 
Mini-PROTEAN
®
TGX
TM
 Precast Gels
*
 
BIO-RAD 
USA 
WesternBright Chemilumineszenz Substrat 
Sirius  
Biozym Scientific GmbH 
SuperSignal
®
 West Femto Maximum 
Sensitivity Substrate 
Thermo scientific, USA 
*The new Mini-PROTEAN and Criterion TGX (Tris-Glycine eXtended) Stain-Free precast gels for PAGE are 
based on the long-shelf life TGX formation and include unique trihalo compounds that allow rapid fluorescent 
detection of proteins with stain-free enabled imagers (for example, Chemiluminescence and Fluorescence 
Instruments (60-FU-SOLO) in our Lab.). The trihalo compounds react with tryptophan residues in a UV-induced 
reaction to produce fluorescence, which is easily detected by stain-free enabled imagers within gels. 
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3.4 Antibodies 
Antibody Dilution Manufacturer 
First antibodies 
Anti-ADAM8 (goat polyclonal lgG) 1:2000 Santa Cruz Biotechnology 
Anti-CD23(rat monoclonal) 1:100 Roche Diagnostics 
Anti-integrin α5 rabbit Ab 1:1000 Cell Signaling Technology 
Anti-integrin β1 rabbit Ab 1:1000 Cell Signaling Technology 
Anti-p-Akt  rabbit Ab 1:1000 Cell Signaling Technology 
Anti-p-ERK1/2 Ab 1:2000 Cell Signaling Technology 
Anti-β-Tubulin (H-235) rabbit 
polyclonal 
1:500 Santa Cruz Biotechnology 
Secondary antibodies 
Anti-goat IgG, HRP-conjugated 1:2000 R&D systems 
Anti-rat lgG, HRP-linked 1:2000 Cell Signaling Technology 
Anti-rabbit IgG, HRP-linked  1:2000 Cell Signaling Technology 
Dnk pAb to Rb IgG(HRP) 1:4000 Abcam
®
 
 
3.5 Protein ladder 
PageRuler™ Plus Prestained Protein ladder is manufactured by Pierce Biotechnology, 
Thermo Scientific, USA. 
 
 
 
 
 
 
 
Materials 
16 
 
3.6 Buffers and Solutions 
Buffer and Solutions Ingredients 
Equilibration buffer 50 mM Tris, 150 mM NaCl 
5×loading buffer 
3.125 ml 1 M Tris PH 6.8, 1 g SDS, 4.5 ml Glycerol, 125 µl 
1% BPB, 1.25 ml β-Mercaptoethanol 
RIPA buffer 
50 mM HEPES PH 7.4, 150 mM NaCl, 1% NP-40,  
0.5% Sodium Deoxycholate,  
0.1% SDS+1×complete protease inhibitor, 1×Phosstop 
10×Running buffer 144 g Glycine, 30 g Tris Base, 10 g SDS to 1 L with ddH2O 
10×Transfer buffer 144 g Glycine, 30 g Tris Base to1 L with ddH2O 
1×Transfer buffer 
(Western Blot) 
100 ml 10×Transfer buffer,  
200 ml Methanol to 1L with ddH2O 
5% Milk blocking 
solution 
5 g no-fat dry milk powder, 100 µl Tween 20,  
100 ml PBS (1×) 
Substrate assay buffer 
1 ml 1 M Tris PH 8.0, 500 µl 1 M CaCl2, 50 µl 1 mM 
ZnCl2, 1 µl Brij
® 35 solution to 50 ml with ddH2O 
 
3.7 Inhibitor (CT1746) 
CT1746(N1-[2-(S)-(3,3-dimethylbutanamidyl)]-N4-hydroxy-2-(R)-[3-(4-chloropheny
l)-propyl] succinamide; Ref.15; obtained from CellTech, now UCB) has Kis against 
human gelatinase A, gelatinase B, stromelysin 1, collagenase, and matrilysin of 0.04, 
0.17, 10.9, 122, and 136 nM, respectively (Kis performed by Jimi P. O'Connell, Cell 
tech Therapeutics Ltd.). It has negligible activity (>40µM) against other classes of 
metalloproteinase such as neprilysin (EC 24. 11), meprin, peptidyl dipeptidase A 
(ACE), and aminopeptidase N, and, at a concentration of 1 mM, has no apparent 
cytotoxicity
35
.
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4. Methods 
 
4.1 Cloning of human ectodomain ADAM8 (hEctoA8) constructs 
C-terminally 6×His tagged hEctoA8 constructs were generated by PCR using 
cloning primers (hA8SgfI 5'-GAGGCGATCGCCATGCGCGGCCTCGGGCTC-3', 
hA8MluI 5'-GCGACGCGTGGGTGCTGTGGGAGCTCC-3') and ligated into the 
pCMV6 expression vector (Origene) using the MluI and SgfI restriction sites, 
respectively. 
 
4.2 Generation of HEK-293 expression recombinant hEctoA8 cells 
HEK-293 cells were transfected with C-terminally 6×His tagged hEctoA8 constructs 
(cloned in pTarget) and the pRFP-C-RS vector (Origene) encoding for red 
fluorescence protein (RFP). Control cells were transfected with RFP vector only. 
Twenty-four hour after transfection, cells were treated with the Resistant RFP-positive 
cells were isolated by fluorescence-activated cell sorting (FACS). C-terminally 6×
His tagged HEctoA8 expression in single-cells clones was analysed by western blot 
and quantitative reverse transcription PCR. 
 
4.3 Generation of Panc1 expression CD23 cells 
Panc1 cells were transfected with pIRESCD23-HA tagged constructs that was kind 
gift of Professor Zena Werb (San Francisco, USA) as the same way as generation of 
HEK-293 expression recombinant hEctoA8 cells.  
 
4.4 Recombinant hEctoA8 transfected HEK cell culture 
Recombinant hEctoA8 transfected HEK cells were cultivated in 15 ml growth 
medium (containing 10% heat-inactivated fetal bovine serum, 1% non essential amino 
acids, 1% sodium pyruvate, 1% streptomycin, 1% Zell Shield
TM
 (the anti 
Methods 
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contamination additive for cell cultures, Minerva Biolabs GmbH) and 2% G418) in 75 
cm
2
 flask. The cells were confluent in 75 cm
2
 flask and then were divided into four 
175 cm
2
 flasks in 20 ml growth medium. The serum free medium 20 ml without 
phenol red was exchanged to the flask when the cells were confluent; the cells were 
incubated for 5 days and supernatant were collected and centrifuged at 4,000 rpm for 
10 min to eliminate cell debris. Fresh supernatants were used directly for purification 
or stored at -80
o
C. 
 
4.5 Recombinant hEctoA8 purification 
TALON Resin was thoroughly re-suspended and equilibrated; the supernatant 
collected previously was added to the resin and the mixture was gently agitated on a 
platform shaker to allow his-tagged protein to bind the resin at 4
o
C for 1-2 h; then the 
mixture was centrifuged at 700× g for 5 min and as much supernatant as possible 
without disturbing the resin pellet was removed carefully; the resin pellet was wash 
by Equilibration Buffer thoroughly; one bed volume of Equilibration Buffer was 
added to the resin and re-suspended by vortexing, the resin was transfered to a 2 ml 
gravity-flow column with an end-cap in place, and the resin was allow to settle out of 
suspension, the end-cap was removed and the buffer was allowed to drain until it 
reached the top of the resin bed, making sure no air bubbles were trapped in the resin 
bed; the his-tagged proteins were eluted by adding 5 bed volumes of Elution Buffer to 
the column and the eluate was desalted by PD-10 Desalting column with equilibration 
buffer and collected in 500 μl fractions; the concentration of recombinant hEctoA8 in 
eluate was measured with NanoDrop-1000 (peQLab). As shown by Fig.5. 
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Figure 5: Schematic diagram of TALON affinity chromatography 
 
4.6 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Gel Ingredient 
Stacking 
gel 
30% Acrylamide  0.333 ml 
1M Tris PH 6.8  0.25 ml 
ddH2O  1.385 ml 
10% SDS  20 µl 
10% APS  20 µl 
TEMED  2 µl 
Separating 
gel 
30% Acylamide  1.667 ml 
1M Tris PH 8.8  1.875 ml 
ddH2O  1.364 ml 
10% SDS  50 µl 
10% APS  40 µl 
TEMED  4 µl 
 
4.7 Silver Staining 
The recombinant hEctoA8 protein purified by TALON affinity was separated via 10% 
SDS-PAGE gel electrophoresis. Then the gel was washed in ultrapure water for 5 min 
(×2) and fixed in 30% ethanol: 10% acetic acid solution (i.e., 6:3:1 water: ethanol: 
acetic acid) for 15 min (×2). Subsequently, the gel was washed in 10% ethanol 
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solution for 5 min (×2) and incubated in Sensitizer Working Solution for exactly 1 
min and washed with two changes of ultrapure water for 1 min each, then the gel was 
incubated in Stain Working Solution for 30 min. Subsequently, the gel was quickly 
washed with two changes of ultrapure water for 20 seconds each and developed in 
Developer Working Solution until the protein bands appeared.  
 
4.8 Protease activity assay 
Synthetic fluorescence resonance energy transfer (FRET)-based polypeptide protein 
substrates have been developed to estimate the protein activity in real-time mode. 
These substrates are typically composed of a FRET donor and a quencher fluorophore, 
which are linked by a sequence of amino acid containing a protease cleavage motif. 
Once the polypeptide is cleaved by the protease, the fluorophore donor separates from 
the quencher resulting in an increase of fluorescence. Thus, protease activity 
dynamics can be monitored by tracking the fluorescence changes over time
16 
(Fig.6). 
PEPDAB013 (Dabcyl-His-Gly-Asp-Gln-Met-Ala-Gln–Lys-Set-Lys (5-FAM)-NH2) 
was used as specific substrate for recombinant hEctoA8. The substrate was stored in 
DMSO at -20
o
C in a stock solution of 10 mM. After diluting the substrates 1:500 with 
activity buffer, we added 12.5 µl eluate of recombinant hEctoA8, 37.5 µl activity 
buffer and 50 µl substrate assay buffer per well in triplicate in a 96-well-plate. For 
blank wells, 12.5 µl equilibration buffer, 37.5 µl activity buffer and 50 µl substrate 
assay buffer were added per well. Fluorescence was measured every 2 min with 
excitation and emission wavelengths of 485 and 530 nm for 180 cycles (6 h), 
respectively.  
For inhibitor of BB-94 and CT-1746, purified recombinant hEctoA8 was incubated 
with 1nMol of BB-94, CT-1746 (10 µMol, 1 µMol, 100 nMol, 10 nMol and 1 nMol) 
for 1 h at room temperature (RT) respectively before activity assay. 
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Figure 6: Schematic diagram of polypeptide cleaved by the protease 
These substrates are typically composed of a FRET donor and a quencher fluorophore, which are linked by a 
sequence of amino acid containing a protease cleavage motif. Once the polypeptide is cleaved by the protease, the 
fluorophore donor separates from the quencher resulting in an increase of fluorescence. 
 
4.9 Purified recombinant hEctoA8 cleaved CD23 from transfected Panc1 cells 
Recombinant hCD23 transfected pancreatic cells were grown in DMEM growth 
medium (containing 10% heat-inactivated fetal bovine serum, 1% non essential amino 
acids, 1% sodium pyruvate, 1% streptomycin, 1% Zell Shield
TM
 and 2% G418) in 
75cm
2
 flask. When the cell is confluent in the flask, cell monolayer was detached by 2 
ml trypsin/EDTA and cells were diluted to 400/µl, 50 µl cells dilution was planted in 
96-well-plate. The serum free medium 50 µl without phenol red was exchanged to the 
wells as control group, recombinant hEctoA8 1 µg and 2 µg mixed with serum free 
medium without phenol red (the total volume 50 µl) was exchanged respectively next 
morning. The supernatant was collected after 1 h, 6 h and overnight for western blot 
directly or stored in -20
o
C. 
 
4.10 FN cleavage assay 
For recombinant hEctoA8 mediated human FN cleavage, 3 µg, 1.5 µg and 0.75 µg 
recombinant hEctoA8 were incubated with 3 µg human FN and activity buffer for 48 
in 37
o
C water bath. Recombinant hEctoA8 inhibitor, BB94 1 nMol was added to 3 µg 
recombinant hEctoA8 with activity buffer and pre-incubated at 37
o
C for 1h and then 
add FN incubating for 48 h. Recombinant hEctoA8 3 µg with activity buffer and FN 
with activity buffer as control groups also incubated in 37
o
C water bath for 48 h. The 
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total volume is 60 µl. 
After incubation, the mixed solutions were collected and separated using 
Mini-PROTEAN
®
TGX
TM
 Precast Gels via electrophoresis and the bands on the gel 
were shown by rapid fluorescent detection of proteins with stain-free enabled imagers, 
then the bands were isolated from the gel and send to Dr. Oliver Schilling (Freiburg 
University) for analysis of FN fragments by Mass Spectrometry. 
  
4.11 FN coating procedure 
24-well-plate was coated with 200 µl/well of 20 µg/ml FN in PBS and incubated 
overnight (or longer) in the cold (2–8 °C). Then the plate was rinsed with PBS after 
the remaining solution was carefully aspirated. Subsequently, blocking buffer 2–5% 
BSA in PBS was added to the wells at least 1 h at room temperature or overnight at 
2–8 °C (200 µl/well). Blocked plates can be stored, as is, in the refrigerator for several 
weeks or can be decanted and dried and stored for months in a dessicator. Desiccated 
material should be rehydrated for 15 min with PBS before use. 
Caution: The BSA solution needs to be filtered to remove excess non-specific sticking 
in the assay caused by insoluble BSA clumps (RIA-grade BSA is usually 
recommended). Unfiltered material may look clear but the filters will clog while 
passing the BSA so it is recommended to use prefilters on top of the filter bed to 
increase the amount of material that will pass. 
 
4.12 Adhesion assay 
24 well culture plates were coated described as FN coating procedure; wells coated 
with PBS were used as negative controls. Recombinant hEctoA8 treatments were 
prepared by diluting recombinant hEctoA8 to various concentrations to a volume of 
150 µl/well with activity buffer. BB94 1 nMol was added to recombinant hEctoA8 10 
µg with activity buffer and was pre-incubated at RT for 1 h, then all treatment groups 
were added to the FN coated well for 24 h at 37
o
C. Panc1_WT and Panc1_A8 were 
grown to confluence in DMEM media in 75 cm
2
 flasks, respectively, and cells were 
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washed with PBS for one time and harvested with Trypsin EDTA. Cells were 
centrifuged and cell pellet was reconstituted in DMEM media. 2×10
5 
cells in 150 µl 
were then seeded on the wells that were pretreated with recombinant hEctoA8 as 
described above.  
Cells were then incubated for 30 min at 37°C to allow for adhesion. Non-adherent 
cells were removed by pipetting out the media, followed by washing the wells for 3 
times with PBS. Adherent cells were fixed with 4%PFA for 15 min at room 
temperature (RT), and then incubated with Hoechst (1:1000 in PBS) for 10 min at RT, 
and washed with PBS for 3 times. 
To maximize the area to be examined for the adherent cell quantification, wells were 
photographed at 3 conserved areas using Leica fluorescence microscope (×50 
magnification). Cells were counted by the software ImageJ. Experiments were 
repeated at least 3 times with 3 triplicates per condition. 
 
4.13 Western Blot 
Western blot was used to detect recombinant hEctoA8 purified by Talon affinity 
chromatography and soluble CD23 fragments cleaved by recombinant hEctoA8 
described as previously, expression of integrin 51 and activation of so p-ERK1/2 
and p-AKT of protein samples described as follows:  
24 well culture plates were coated described as FN coating procedure; wells coated 
with PBS were used as negative controls. Recombinant hEctoA8 treatments were 
prepared by diluting 10 µg recombinant hEctoA8 to a volume of 150 µl/well with 
activity buffer. BB94 1 nMol was added to the recombinant hEctoA8 10 µg with 
activity buffer and was pre-incubated at RT for 1 h. Then, all treatment groups were 
added to the FN coated well for 24 h at 37
 o
C. Panc1 cells were grown to confluence 
in DMEM media in 75 cm
2
 flask, cells were washed with PBS for one time and 
harvested with Trypsin EDTA. Cells were centrifuged and the cell pellet was 
reconstituted in DMEM medium. 2×10
5 
cells in 150 µl were then seeded on the wells 
that were pretreated with recombinant hEctoA8 as described above. Cells were then 
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incubated for 4 h at 37 °C to allow for all cells adhesion and cells were lysed in RIPA 
buffer and stored at -20 °C for western blot. 
Protein samples were separated via 10% SDS-PAGE gel electrophoresis and 
electroblotted onto Protran
®
nitrocellulose membranes (Whatman GmbH). 
Nonspecific binding sites were blocked by incubating nitrocellulose membrane for 1h 
in phosphate-buffered saline containing 5% low-fat dry milk. Membranes were 
incubated overnight at 4°C with primary antibodies (listed in 3.4 antibodies) and for 1 
h at room temperature with secondary antibody linked HRP (Horseradish peroxidase) 
(listed in 3.4 antibodies). Blots on the membrane were developed using 
WesternBright Chemilumineszenz Substrat Sirius (Biozym Scientific GmbH) 
according to the manufacture’s instruction. Exposing the membrane to a luminescence 
reader (Intas, Chemostar Imager) provides an image of the proteins bound to the blot. 
The Western analysis was made in triplicates. The density of specificbands was 
measured with a computer-assisted imaging analysis systemand normalized against 
loading controls. Differences were compared using repeated measure one-way 
ANOVA. 
 
4.14 Statistical analysis 
Results were expressed as the mean ± SEM of at least three separate experiments. 
Results were analyzed by one-way ANOVA followed by the Fisher's Least Significant 
Difference (LSD) test. Differences with p values of <0.05 were considered significant. 
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5. Results 
 
5.1 Purification of recombinant hEctoA8 and its activity assay 
The protein recombinant hEctoA8 secreted from transfected HEK-293 cells was 
purified and identified by western blot, purity of recombinant hEctoA8 protein was 
analysed by silver staining. As shown in Fig 6, purified recombinant hEctoA8 from 
the supernatant of transfected HEK cells contained two types of protein (molecular 
mass 100 and 70 kDa). 
In the crude supernatant and in purified fractions, catalytic activity of recombinant 
hEctoA8 was tested using a peptide derived from the cleavage sequence of 
CD23-PEPDAB013 Dabcyl-His-Gly-Asp-Gln-Met-Ala-Gln-Lys-Ser-Lys 
(5-Fam)-NH2) by a FRET assay (Fig 7). Within 6 hours of incubation, there was 
significant cleavage of PEPDAB013 in the recombinant hEctoA8 fractions. As control, 
no cleavage was observed in a recombinant human ADAM8 protein consisting of only 
the disintegrin, cysteine-rich and EGF-like domain of ADAM8 (rhDCEA8). 
 
 
 
 
 
 
 
 
 
Figure 7: Purification of recombinant hEctoA8 and its proteolytic activity. 
Purification of recombinant hEctoA8 from transfected HEK cells analysed by western blot, silver stain, and 
fluorescence determination of recombinant hEctoA8 activity using substrate PEPDAB013; relative fluorescence 
intensities increased with incubation time prolonging in PEPDAB013 mixed with recombinant hEctoA8 in the 
presence of activity buffer (blue line), compared to purified rhDCEA8 domain which has no proteolytic activity 
(red line). 
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5.2 The effect of BB-94 (Batimastat) and CT1746 on activity of recombinant 
hEctoA8 
We next tested if a synthetic inhibitor CT1746 is able to block activity of recombinant 
hEctoA8 and compared its blocking ability to the broad range metalloproteinase 
inhibitor BB94 known to inhibit ADAM8
3
.
 
Purified recombinant hEctoA8 was 
incubated with 1nMol of BB-94 and CT-1746 (10 µMol, 1 µMol, 100 nMol, 10 nMol 
and 1 nMol) for 1 h respectively before the activity assay. In these assays, BB-94 
1nMol resulted in completely blocking the activity of recombinant hEctoA8, CT-1746 
10 µMol resulted in partially blocking the activity of recombinant hEctoA8. Thus 
CT-1746 has no inhibitory effect on recombinant hEctoA8 activity in the lower 
micromolar range (Fig.8). 
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Figure 8: The effect of BB-94 and CT-1746 on activity of recombinant hEctoA8 
Effect of treatment with BB-94 and different concentration of CT-1746 on relative fluorescence intensities (FI) of 
recombinant hEctoA8 cleavage sequence of PEPDAB013, BB94 (1 nMol) resulted in completely blocking activity 
of recombinant hEctoA8 (**=p<0.01 vs. EctoA8 group); CT1746 10 µMol resulted in partially blocking activity of 
recombinant hEctoA8 (*=p<0.05 vs. EctoA8 group); no difference was found in other groups. 
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5.3 Cleavage of CD23 protein from transfected Panc1 cells by recombinant 
hEctoA8 
To test if recombinant hEctoA8 can be used to cleave a substrate in trans, Panc1 cells 
were transfected with CD23 cDNA, after the generation of stable lines by selection 
with G418, recombinant hEctoA8 1 µg and 2 µg were incubated with CD23 
transfected Panc1 cells in phenol red-free medium, the supernatant was collected after 
1 h, 6 h and overnight for western blot.  
In our study, we found that the CD23 cleaved by recombinant hEctoA8 from Panc1 
cell surface yielded soluble CD23 (sCD23) proteins of 37, 33, 25 and 16 kDa. 
Compared to control group, CD23 transfected Panc1 cells incubated with recombinant 
hEctoA8, more sCD23 could be detected in the medium in recombinant hEctoA8 1 µg 
and 2 µg groups at the time point of 1 h (p<0.05); the sCD23 proteins of 25 and 16 
kDa were more detected at the time point of 6 h compared to control group (p<0.05); 
no difference was found at the time point of overnight for different groups. Compared 
to recombinant hEctoA8 1µg group, the sCD23 proteins of 37, 33 and 25kDa were 
more detected at the time point of 1 h in recombinant hEctoA8 2 µg group (p<0.05) 
(Fig.9).  
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Figure 9: Cleavage of protein CD23 by different dosages of recombinant hEctoA8 from transfected Panc1 
cells analysed by western blot at different time points  
A: Release of sCD23 by proteolytically active recombinant hEctoA8 from Panc1 stably transfected with CD23 
cDNA. Cells were incubated with recombinant hEctoA8 for 1 h, 6 h and overnight, respectively, and the 
supernatants were analysed by SDS-PAGE, transferred to nitrocellulose membrane, and analysed by Western blot 
for the presence of sCD23 in the medium. B: Compared to control group, CD23 transfected Panc1 cells incubated 
with recombinant hEctoA8, more soluble CD23 was detected in the medium after incubation with recombinant 
hEctoA8 (1µg and 2µg) at time point 1 h (*=p<0.05 vs. control group, **=p<0.01vs. control group). Compared to 
recombinant hEctoA8 1 µg group, the sCD23 proteins of 37, 33 and 25 kDa were more detected in recombinant 
hEctoA8 2 µg group at time point 1 h (#=p<0.05 vs. EctoA8 1µg group). C: The sCD23 proteins of 25 and 16 kDa 
were increased at time point 6 h compared to control group (*=p<0.05 vs. control group). The Western blot 
analysis was made in triplicates. 
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5.4 FN cleaved by recombinant hEctoA8 in vitro 
Soluble recombinant hEctoA8 was isolated and purified from supernatants of 
transfected HEK cells according to the protocol, the protein preparations were used in 
different amounts for cleavage assays with FN as a substrate (Fig.10). Purified 
recombinant hEctoA8 and FN served as controls. When recombinant hEctoA8 was 
incubated with FN, cleavage resulted in 9 fragments of different molecular weights. 
As additional control, metalloproteinase inhibitor BB94 was used to inhibit 
recombinant hEctoA8 proteolytic activity. BB94 (1 nMol) completely inhibited 
recombinant hEctoA8 activity.  
 
 
 
                   
 
 
 
 
 
 
                  
 
 
 
 
 
 
 
Figure 10: FN cleaved by recombinant hEctoA8 in vivo 
Purified recombinant hEctoA8 proteases tested with FN. The bands were separated using Stain-Free precast gels 
and shown by stain-free enabled imagers. The 1st lane shows FN alone and the 2st lane shows recombinant 
hEctoA8 alone, the 3st lane to 5th lane showed that 3 µg (+++), 1.5 µg (++) and 0.75 µg (+) recombinant hEctoA8 
was incubated 3 µg (+) FN for 24 h at 37 oC, the 6th lane showed that the cleavage reaction of 3 µg (+) FN with 3 
µg (+++) recombinant hEctoA8 was performed in the presence of BB94 (1 nMol). 
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5.5 MS analysis of FN fragments cleaved by recombinant hEctoA8 
The fragments of FN detailed from recombinant hEctoA8 cleavage (Fig.10) were 
isolated from the gel, digested with sequence/grade trypsin and the resulting peptide 
fragements were subsequently analysed by Mass Spectrometry (Fig.11) (see 
appendix9.1): 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: MS analysis of FN fragments cleaved by recombinant hEctoA8  
A: Schematic representation of FN fragments cleaved by recombinant hEctoA8. B: Fragment sequences analysed 
by Mass Spectrometry and predicted molecular weights (MW) shown in the table. 
 
5.6 Recombinant hEctoA8-mediated cleavage of FN reduced human pancreatic 
cells adhesion 
To further explore if recombinant hEctoA8-mediated cleavage of FN affect tumor cell 
adhesion, FN coated wells were treated with increasing concentration of recombinant 
hEctoA8 at 37°C for 24 h. 2×10
5 
cells in 150 µl were then seeded in the wells that 
were pretreated with recombinant hEctoA8 as described above. Recombinant 
hEctoA8 treatment resulted in a dose-dependent decrease in pancreatic cells 
adherence to FN-coated wells. This decrease reached significance (p<0.05) when 
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recombinant hEctoA8 was used in amounts of 1 µg, 5 µg and 10 µg. Pre-incubation of 
10 µg recombinant hEctoA8 with 1 nMol of BB94 restored pancreatic cells adhesion 
to FN-coated wells (p<0.05), while treating the wells with BB94 alone showed no 
difference in cell adhesion compared to FN-coated wells (p>0.05). Non-specific 
adherence of cells to the wells was negligible in the experimental condition as only 
low number of cells adhered to wells that were coated with PBS in the control group. 
Compared to the Panc1_WT cell line, more Panc1_A8 cells attached to the coated 
plate with high significance (p<0.01) (Fig.12, Fig.13, Fig.14). 
A 
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Figure 12: Adhesion assay with Panc1_WT cells 
A: Representative images (50×) of adherent Panc1_WT cells on FN-coated (20 µg/ml) wells pre-treated with 
increasing concentrations of recombinant hEctoA8 with or without BB94 (inhibitor) (1nMol) and with BB94 alone. 
B: Quantification of adherent cells. Results are presented as mean ±SEM of n=3 with three triplicates per 
condition (*= p<0.05 vs. Fib group, **=p<0.01 vs. Fib group, #=p<0.05 vs. Ecto10+Fib group). Pre-coated wells 
with PBS were used as negative control. 
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Figure 13: Adhesion assay with Panc1_A8 cells 
A: Representative images (50×) of adherent Panc1_A8 cells on FN-coated (20 µg/ml) wells pre-treated with 
increasing concentrations of recombinant hEctoA8 with or without BB94 (inhibitor) (1 nMol) and with BB94 
alone. B: Quantification of adherent cells. Results are presented as mean ±SEM of n=3 with three triplicates per 
condition (*=p<0.05 vs. Fib group, **=p<0.01 vs. Fib group, #=p<0.05 vs. rhEcto10+Fib group). Pre-coated wells 
with PBS were used as negative control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Quantification of cells adhesion for Panc1_ WT cells vs. Panc1_A8 cells  
Adhesion of Panc1_ WT cells vs. Panc1_A8 cells, the number of cells was counted by the software ImageJ. 
Results are presented as mean ±SEM of n=24 with three triplicates per condition. Compared to Panc1_ WT cells, 
the number of Panc1_A8 cells attached much more (**=p<0.01 vs. Pan_ WT group). 
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5.7 Effect of FN cleavage on integrin α5 expression 
Since the classical fibronectin receptor on the cell membrane is integrin 51, we 
sought to explore whether integrin α5 is involved in recombinant hEctoA8-mediated 
FN cleavage reducing tumor cells adhesion, so the levels of integrin α5 were analysed 
in different treatment groups as follows. Panc1 cells expressing integrin α5 weakly 
was considered as control group; the expression of integrin α5 increased significantly 
in the presence of FN (p<0.01); when pretreated with recombinant hEctoA8; the 
expression of integrin α5 was significantly decreased (p<0.05); when pretreated with 
BB94 for blocking the activity of recombinant hEctoA8, the expression of integrin α5 
was partly restored (p<0.05); the activity buffer had no effect on the expression of 
integrin α5 (Fig.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Expression of integrin α5 determined by western blot  
In the presence of FN, the expression of integrin α5 was increased significantly (††=p<0.01 vs. control group); 
Pretreated with recombinant hEctoA8, the expression of integrin α5 decreased (*=p<0.05 vs. Fib group); 
Pretreated with BB94 to block the activity of recombinant hEctoA8, the expression of integrin α5 was partly 
restored (#=p<0.05 vs. Fib+EctoA8 group). The Western blot analysis was made in triplicates. 
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5.8 Effect of FN cleavage on integrin β1 expression  
As -subunit, integrin β1 is part of the FN receptor. Integrin 1 can form heterodimers 
with the most different alpha-subunits (at least 11), 12 different integrins formed 
heterodimers with integrin β1 that all bind to ECM protein ligands, namely collagen, 
laminin, fibronectin, tenascin C and vitronectin
36
. Thus, we explored whether integrin 
β1 is involved in recombinant hEctoA8-mediated FN cleavage that reduces tumor 
cells adhesion. Western blot results showed that in contrast to 5 subunit expression, 
the cellular concentration of integrin β1 is not changed in the reduction of Panc1 cell 
adhesion caused by ADAM8-dependent cleavage of FN (Fig.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Expression of integrin β1 determined by western blot 
Panc1 cells were seeded on FN coated plates as positive control and cells were seeded on PBS coated plates as 
negative control, cells were then incubated for 4 h 37 °C to allow for all cells adhesion and cells were lysed in 
RIPA buffer for western blot. The expression of integrin β1 showed no difference in different groups. The Western 
blot analysis was made in triplicates. 
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5.9 Effect of FN cleavage on activation of p-ERK1/2 and p-Akt 
To explore whether recombinant hEctoA8-mediated FN cleavage affects signal 
transduction in Panc1 cells, expression of activated p-ERK1/2 and p-Akt were 
analysed in different treatment groups (Fig.17, 18). No significant difference was 
found; so that we concluded recombinant hEctoA8-mediated FN cleavage does not 
affect activation of p-ERK1/2 and p-Akt in Panc1 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Expression/Activation of p-ERK1/2 determined by western blot 
Panc1 cells were seeded on FN coated plates as positive control and cells were seeded on PBS coated plates as 
negative control, cells were then incubated for 4 h 37 °C to allow for all cells adhesion and were lysed in RIPA 
buffer for western blot. The activation of p-ERK1/2 showed no difference in different groups. The Western blot 
analysis was made in triplicates. 
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Figure 18: Expression/Activation of p-Akt determined by western blot 
Panc1 cells were seeded on FN coated plates as positive control and cells were seeded on PBS coated plates as 
negative control, cells were then incubated for 4 h 37 °C to allow for all cells adhesion and were lysed in RIPA 
buffer for western blot. The activation of p-Akt showed no difference in different groups. The Western blot 
analysis was made in triplicates. 
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6. Discussion 
 
6.1 Purification of recombinant hEctoA8 from transfected HEK cells 
In our studies, we successfully purified biologically active recombinant hEctoA8 
protein expressed in stably transfected HEK-293 cells. Western blot analysis using 
goat anti-hA8 antibody confirmed that the recombinant hEctoA8 protein is present in 
HEK cell supernatants; SDS-PAGE silver staining analysis confirmed the purity 
obtained using TALON affinity chromatography. The recombinant hEctoA8 purified 
by TALON affinity yielded protein bands with apparent molecular weights of 100 
kDa and 70 kDa which represent the proform and the activated form of recombinant 
hEctoA8. The theoretical molecular weight for full-length recombinant hEctoA8 is 
~92 kDa. The slightly higher apparent molecular weight (100 kDa) for the proform of 
recombinant hEctoA8 is likely to be due to post-translational modifications, as shown 
earlier by Schlomann et al.
3
. Removal of the prodomain was shown by Schlomann et 
al. to result in a molecular form of 72 kDa, so presumably the 70 kDa band we 
observed represents active recombinant hEctoA8
3
.  
 
6.2 Proteolytically active function of recombinant hEctoA8 
To investigate recombinant hEctoA8 catalytic activity, a peptide derived from CD23 
as a known substrate of ADAM8
16 
was used to monitor activity as fluorescence 
increase. This setup allows for identification of ADAM8 inhibitors. We found that in 
the absence of inhibitors, recombinant hEctoA8 cleaves the CD23 peptide efficiently, 
consistent with the previous studies that ADAM8 cleavage was observed at two 
adjacent amino acid residues (SNQLAQ/K/SQV) for CD23
14
. The 
hydroxamate-based MMP inhibitor CT1746 (obtained from Cell Tech, now UCB) was 
tested for inhibition of recombinant hEctoA8 catalytic activity. With different 
concentrations of CT1746, we only found that CT1746 10 µmol partially blocked the 
catalytic activity of recombinant hEctoA8. Since efficient hydroxamate inhibitors 
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inhibit MMPs/ADAMs in a nanomolar range. CT1746 is not an effective inhibitor for 
recombinant hEctoA8 activity, as compared to BB-94, which has an IC50 value of ~50 
nM for ADAM8
3
. 
Given the functionality of the recombinant hEctoA8, we were further interested in 
analysing the possibility of CD23 shedding by hEctoA8 from CD23 expressing cells. 
This experimental setup is similar to CD23 release by soluble ADAM8 MP domain 
released from adjacent cells, i.e. in trans. To investigate this, purified recombinant 
hEctoA8 was incubated with Panc1 cells stably expressing full-length CD23. It was 
found that CD23 cleaved by recombinant hEctoA8 from Panc1 cells yielded soluble 
CD23 (sCD23) fragments of 37, 33, 25, and 16 kDa molecular weight. Some of these 
fragments were reported to be released from the cell surface of cells when ADAM8 
was present on the cell membrane, i.e. in cis
15
.
 
Our finding is consistent with the 
results that under physiological conditions, CD23 can be released from the cell 
surface as a range of diffusible sCD23 proteins which could play an important role for 
the up-regulation of IgE synthesis by interaction with B cells
25
.  
CD23, the low affinity IgE receptor, is expressed on B cells, monocytes, macrophages, 
and eosinophils 
37
and is cleaved from the cell surface to generate a number of soluble 
forms. Both membrane-bound and soluble forms of CD23 have been shown to be 
elevated in a number of diseases such as asthma, rheumatoid arthritis, and 
inflammatory bowel disease
24
. Soluble forms of CD23, in addition to their role for the 
up-regulation of IgE synthesis by interaction with B cells 
25
, can promote the 
induction of inflammatory cytokines by macrophages
24
. So membrane-bound as well 
as soluble ADAM8 involved in shedding and cleaving of CD23 may be the basis of 
pathophysiology of these diseases. 
 
6.3 FN cleaved by recombinant hEctoA8 
Another ADAM8 substrate that was analysed is human plasma FN used in our studies. 
In vitro, recombinant hEctoA8 was incubated with FN, and the cleavage resulted in 
products with approximate molecular weights of 169, 129, 119, 110, 91, 38, 31, 22.4 
and 12 kDa. Of these fragments, the fragment of 38 kDa could be of great interest, 
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since this fragment contains the RGD motif that is critical for cell adhesion. FN is a 
core component of many extracellular matrices where it regulates a variety of cell 
activities through direct interactions with cell surface integrin receptors
38
. FN matrix 
is important for normal cell adhesion and growth; both decreased expression and 
elevated degradation of FN have been shown to be responsible for some of the 
morphological changes observed in tumors and tumor-derived cell lines
38
. As a major 
protein in blood and a component of the wound provisional matrix, plasma FN 
contributes to tissue repair and neuronal survival following cerebral ischemia
39
. 
Clearly, FN is a key component in many ECM-dependent processes in vivo. Ruel et al. 
have identified FN in intervertebral disc (IVD) tissue and found that FN-fragments 
cleaved by ADAM8 play important role for initiation and progression of disc 
degeneration, they found 25- and 29-kDa FN-fragments cleaved by ADAM8 existed 
in the degenerative IVD of surgical tissue
32
.
 
Our finding confirmed that recombinant 
hEctoA8 with its catalytic function of ADAM8 can cleave FN into 9 different 
fragments which included 31- and 22.4- kDa fragments that have the similar 
molecular weight as demonstrated in the previous study
32
. 
 
6.4 Effect of recombinant hEctoA8 cleavage of FN on pancreatic cell adhesion 
and expression of integrin α5β1 
Recently published data show that ADAM8 has a critical role in pancreatic cancer 
progression
12
. To analyse if the observed FN cleavage has physiological consequences 
such as influencing adhesion/de-adhesion of tumor cells, Panc1_WT and Panc1_A8 
cells overexpressing ADAM8 were seeded out on a plastic surface coated with FN 
either uncleaved or cleaved with hEctoA8. As expected we initially found that 
recombinant Panc1_ A8 tumor cells attached much better to FN coated surface than 
Panc1_WT cells due to the interactions between ADAM8 and FN. These results 
confirmed that ADAM8 itself plays an important role in cell adhesion, consistent with 
a previous study
3
. Moreover, ADAM8 protease cleaves FN
 31 
which affects normal 
cell adhesion and growth
38
. We found that cleavage of FN resulted in reduced tumor 
cell adhesion. The effect on cell adhesion was partially restored with BB-94 present. 
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In addition to the previous studies
40
, we found here that plasma FN is cleaved by 
recombinant hEctoA8 in a dose-dependent manner resulting in decreased cell 
adhesion. 
FN regulates a variety of cell activities through direct interactions with cell surface 
integrin receptors
38
, and previous studies demonstrated that the fate of integrin α5 is 
regulated by matrix-capable FN
41
. In accordance with that we also found that integrin 
α5 levels decrease within 4 h when FN is cleaved by recombinant hEctoA8. The 
status of extracellular FN itself could modulate integrin α5 fate via its impact on the 
binding and activation of other cell-surface receptors
41
. FN in its matrix form is able 
to engage in multidomain interactions with other cell extracellular components
41
. 
Some studies found that cells secrete FN as a disulfide-bonded dimer that binds to the 
integrin α5β1 receptor via the cell-binding domain located in the 10th type 3 repeat of 
FN
42
, but cleavage of FN had no effect on the expression of integrin β1 in our study.  
The essential peptide sequence of the initial FN cell binding domain was identified as 
RGD and subsequently a synergistic sequence PHSRN was identified
43
. Synthetic 
RGD peptides have been created and have facilitated the identification of integrin cell 
surface receptors involved in cell attachment. The sequence of FN fragments analysed 
by Mass Spectrometry showed that the fragment contained RGD peptides cleaved by 
recombinant hEctoA8 located at the amino acid positions 1285-1575 according to our 
results. The classic FN receptor is integrin α5β1 and aberrant expression of this 
receptor has been associated with tumorigenicity
44
. Malignant cell lines are often 
surrounded by matrix with both increased amounts of FN and integrin α5β1 
expression. This integrin participates in the incorporation of FN into matrix and 
increased metastasis
45
. Integrin α5 levels decreased in 4 h later when FN is cleaved by 
recombinant hEctoA8 in our study showed that their interaction play an important role 
in cell adhesion.  
There are two explanations for decreased cell adhesion in the cleavage of FN by 
recombinant hEctoA8. One is that the sequence RGD of FN was cleaved off from the 
total FN by recombinant hEctoA8; the other explanation could be that the receptor of 
FN-integrin α5 is not expressed without stimulation by intact FN. 
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6.5 Effect of recombinant hEctoA8 cleavage of FN on p-ERK1/2 and p-Akt 
activation of pancreatic cells 
ERK1 and ERK2 are 84% identical in sequence and share many if not all functions. 
For this reason they will be referred to as ERK1/2. ERK1/2, like nearly all protein 
kinases, contains unique N- and C-terminal extensions that provide signaling 
specifity
46
. ERK1/2 is a ubiquitous regulator of multiple cellular processes such as 
proliferation, differentiation, survival, and transformation. Activation of ERK1/2 
(p-ERK1/2) can lead to genomic instability and subsequent tumor progression
47
. 
Akt, also known as protein kinase B, is a serine-threonine kinase that comprises a 
family of three different protein isoforms: Akt1, Akt2, and Akt3. Akt is a key 
regulator of PI3K and mTOR signaling, and therefore its activation is an important 
driver of malignant progression and chemoresistance. Activated Akt can 
phosphorylate the tumor suppressor protein tuberous sclerosis protein2 (TSC2 or 
tuberin) to attenuate its negative regulation of PI3K pathway through mTOR 
inhibition
48
. Activation of Akt has been reported in 28/46 (61%) pancreatic tumor 
samples
49
. 
The extracellular matrix (ECM) and cytokines are important mediators of neoplastic 
cells of tumor development process whose net effects are determined by a complex 
series of interactions. Extracellular signals can also alter the expression of ECM 
proteins and cytokines, creating feedback loops that may contribute to tumor 
development
50
. To explore whether recombinant hEctoA8-mediated FN cleavage is 
involved in signal transduction in pancreatic tumor cells, we examined the expression 
of p-ERK1/2 and p-Akt. Our results demonstrated that cleavage of FN by 
recombinant hEctoA8 has no effect on the activation of p-ERK1/2 and p-Akt. 
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7. Conclusion 
 
Purified recombinant hEctoA8 containing the catalytic function of ADAM8 can 
cleave CD23 in cells in trans and FN in vitro; CD23 cleavage resulted in fragments of 
37, 33, 25 and 16 kDa and FN cleavage by recombinant hEctoA8 resulted in 9 
fragments, one fragment of 38 kDa contains a RGD motif essential for cell adhesion. 
Functionally, FN cleavage resulted in reduced tumor cell adhesion and decreased 
expression of integrin α5; however, cleavage of FN by recombinant hEctoA8 has no 
effect on the expression of integrin β1, the activation of p-ERK1/2 and p-Akt. 
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9.  Summary  
 
From recent studies in different tumor entities it became apparent that the 
membrane-anchored metalloprotease-disintegrin ADAM8 plays an active role in 
tumor progression and consequently in patient prognosis. It is therefore desirable to 
understand the functional role of ADAM8 in vitro by characterizing the soluble 
extracellular part of ADAM8, which is called the ADAM8 ectodomain. The human 
ectodomain ADAM8 (hEctoA8) protein consists of the prodomain, metalloprotease 
domain (MP), a disintegrin domain (DIS), a cysteine-rich domain (Cys) and a 
EGF-like domain (EGF), whilst removal of the prodomain by autocatalysis leads to 
the active form of hEctoA8. Like the full-length ADAM8, hEctoA8 contains the 
catalytic consensus sequence HEXXHXXGXXHD in the metalloprotease domain and 
is therefore predicted to be proteolytically active. Up to now, functional studies on 
ADAM8 in vitro were hampered by the lack of sufficient quantities of folded, 
biologically active, and purified recombinant forms of hEctoA8. In our study, we 
successfully purified the recombinant hEctoA8 protein from supernatants of 
transfected HEK cells. Purified recombinant hEctoA8 containing the catalytic 
function of ADAM8 can cleave CD23 in cells in trans and FN in vitro; CD23 
cleavage resulted in fragments of 37, 33, 25 and 16 kDa and FN cleavage by 
recombinant hEctoA8 resulted in 9 fragments, one fragment of 38 kDa contains a 
RGD motif essential for cell adhesion. Functionally, ADAM8-dependent cell adhesion 
of pancreatic tumor cells Panc1 was affected by FN cleavage and resulted in reduced 
cell adhesion. Concomitantly, a decreased expression of integrin α5; was found, 
whereas cleavage of FN by recombinant hEctoA8 had no effect on the expression 
levels of integrin β1, and on the activation of p-ERK1/2 and p-Akt. 
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10. Zusammenfassung 
 
In einer Reihe von klinischen Studien wurde nachgewiesen, dass die 
membranständige Metalloprotease ADAM8 eine Rolle bei der Tumorprogression 
spielt und eine erhöhte ADAM8-Expression mit einer verschlechterten 
Patientenprognose einhergeht. Es ist daher notwendig, die Rolle der 
ADAM8-Aktivität in vitro zu verstehen. In dieser Arbeit sollte daher die lösliche 
Variante von ADAM8, die Ektodomäne (hEctoA8), aufgereinigt und funktionell 
charakterisiert warden. Diese besteht aus der Prodomäne, der 
Metalloprotease-Domäne (MP), der Disintegrin-Domäne (DIS), der Cystein-reichen 
Domäne (Cys) and der EGF-artigen Domäne (EGF). Die autokatalytische Entfernung 
der Prodomäne führt zur aktiven Protease. Wie das gesamte ADAM8-Molekül auch, 
enthält das rekombinanten Protein hEctoA8 die für Metzinkine charakteristische 
Konsensus-Sequenz “HEXXHXXGXXHD” in der MP-Domäne und sollte daher 
proteolytische Aktivität besitzen. Bis heute war es nur schwer möglich, funktionelle 
Studien mit ADAM8 in vitro durchzuführen, da nicht genügend rekombinantes 
Protein mit biologischer Aktivität zur Verfügung stand. In dieser Arbeit wurde das 
rekombinante humane ADAM8 als hEctoA8 erfolgreich aus Überständen von stabil 
transfizierten und selektionierten HEK293 Zellen aufgereinigt. Das so gewonnene 
Protein hEctoA8 besitzt eine hohe katalytische Aktivität und kann in einem 
FRET-basierten Assay ein Fluoreszenz-gequenchtes Peptid spalten, das der 
ADAM8-Spaltstelle im niedrig-affinen IgE Rezeptor CD23 nachempfunden ist. 
Interessanterweise wird auch intaktes membranständiges CD23 von der Oberfläche 
stabiler CD23-exprimierender Zellen in Fragmente von 37, 33, 25 and 16 kDa 
abgespalten, womit erstmalig eine Susbtratspaltung in trans nachgewiesen wurde. 
Weiterhin wurden die ADAM8-Spaltstellen für das extrazelluläre Matrixprotein 
Fibronectin (FN) charakterisiert. Es entstanden dabei 9 FN-Fragmente von 
unterschiedlichem Molekulargewicht. Ein FN-Fragment mit einem Molekulargewicht 
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von 38 kDa war dabei besonders interessant, da es so genannte Zellbindungsdomänen 
sowie ein RGD-Motiv enthält. Durch die ADAM8-abhängige Spaltung dieses 
Fragments kann man davon ausgehen, dass eine durch FN vermittelte Zelladhäsion 
verloren gehen sollte. Diese Hypothese wurde durch Pankreas-Tumorzellen Panc1 
überprüft, bei denen eine ADAM8-abhängige Zelladhäsion auf FN mit und ohne 
vorherigen Verdau gemessen wurde. Es konnte gezeigt werden, dass der Verdau von 
Fibronektin durch ADAM8 die Zelladhäsion signifikant reduzierte. Die Expression 
des daran beteiligten Fibronektin-Rezeptors 51 wurde auf Proteinebene untersucht 
und dabei gezeigt, dass spezifisch die Integrin 5-Untereinheit vermindert ist, 
während die Integrin 1-Untereinheit nicht verändert ist. Auch die vom 
Fibronektin-Rezeptor abhängige Signalkaskade, an der unter anderem die Kinasen 
p-ERK1/2 und p-Akt beteiligt sind, zeigt keine Änderungen im Aktivierungsstatus, 
sodass man daraus schliessen kann, dass die von ADAM8 vermittelte Degradation 
von FN direkt über die Regulation der Integrin 5-Untereinheit zu einer verminderten 
Zelladhäsion führt.
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11.  Appendix 
 
11.1 Sequence of Fibronectin Fragments: 
 
FN1(Position: 1035-2386 Predicted MW: 169KD): RGQPR QYNVGPSVSK YPLRNLQPAS EYTVSLVAIK 
GNQESPKATG VFTTLQPGSS IPPYNTEVTE TTIVITWTPA PRIGFKLGVR PSQGGEAPRE VTSDSGSIVV 
SGLTPGVEYV YTIQVLRDGQ ERDAPIVNKV VTPLSPPTNL HLEANPDTGV LTVSWERSTT PDITGYRITT 
TPTNGQQGNS LEEVVHADQS SCTFDNLSPG LEYNVSVYTV KDDKESVPIS DTIIPAVPPP TDLRFTNIGP 
DTMRVTWAPP PSIDLTNFLV RYSPVKNEED VAELSISPSD NAVVLTNLLP GTEYVVSVSS VYEQHESTPL 
RGRQKTGLDS PTGIDFSDIT ANSFTVHWIA PRATITGYRI RHHPEHFSGR PREDRVPHSR NSITLTNLTP 
GTEYVVSIVA LNGREESPLL IGQQSTVSDV PRDLEVVAAT PTSLLISWDA PAVTVRYYRI TYGETGGNSP 
VQEFTVPGSK STATISGLKP GVDYTITVYA VTGRGDSPAS SKPISINYRT EIDKPSQMQV TDVQDNSISV 
KWLPSSSPVT GYRVTTTPKN GPGPTKTKTA GPDQTEMTIE GLQPTVEYVV SVYAQNPSGE 
SQPLVQTAVT NIDRPKGLAF TDVDVDSIKI AWESPQGQVS RYRVTYSSPE DGIHELFPAP DGEEDTAELQ 
GLRPGSEYTV SVVALHDDME SQPLIGTQST AIPAPTDLKF TQVTPTSLSA QWTPPNVQLT 
GYRVRVTPKE KTGPMKEINL APDSSSVVVS GLMVATKYEV SVYALKDTLT SRPAQGVVTT 
LENVSPPRRA RVTDATETTI TISWRTKTET ITGFQVDAVP ANGQTPIQRT IKPDVRSYTI TGLQPGTDYK 
IYLYTLNDNA RSSPVVIDAS TAIDAPSNLR FLATTPNSLL VSWQPPRARI TGYIIKYEKP GSPPREVVPR 
PRPGVTEATI TGLEPGTEYT IYVIALKNNQ KSEPLIGRKK TDELPQLVTL PHPNLHGPEI LDVPSTVQKT 
PFVTHPGYDT GNGIQLPGTS GQQPSVGQQM IFEEHGFRRT TPPTTATPIR HRPRPYPPNV GEEIQIGHIP 
REDVDYHLYP HGPGLNPNAS TGQEALSQTT ISWAPFQDTS EYIISCHPVG TDEEPLQFRV PGTSTSATLT 
GLTRGATYNV IVEALKDQQR HKVREEVVTV GNSVNEGLNQ PTDDSCFDPY TVSHYAVGDE 
WERMSESGFK LLCQCLGFGS GHFRCDSSRW CHDNGVNYKI GEKWDRQGEN GQMMSCTCLG 
NGKGEFKCDP HEATCYDDGK TYHVGEQWQK EYLGAICSCT CFGGQRGWRC DNCRRPGGEP 
SPEGTTGQSY NQYSQRYHQR TNTNVNCPIE CFMPLDVQAD REDSRE 
 
FN2(Position: 0-1035 Predicted MW: 129KD): MLRGPGPGLL LLAVQCLGTA VPSTGASKSK 
RQAQQMVQPQ SPVAVSQSKP GCYDNGKHYQ INQQWERTYL GNALVCTCYG GSRGFNCESK 
PEAEETCFDK YTGNTYRVGD TYERPKDSMI WDCTCIGAGR GRISCTIANR CHEGGQSYKI 
GDTWRRPHET GGYMLECVCL GNGKGEWTCK PIAEKCFDHA AGTSYVVGET WEKPYQGWMM 
VDCTCLGEGS GRITCTSRNR CNDQDTRTSY RIGDTWSKKD NRGNLLQCIC TGNGRGEWKC 
ERHTSVQTTS SGSGPFTDVR AAVYQPQPHP QPPPYGHCVT DSGVVYSVGM QWLKTQGNKQ 
MLCTCLGNGV SCQETAVTQT YGGNSNGEPC VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTS 
NYEQDQKYSF CTDHTVLVQT RGGNSNGALC HFPFLYNNHN YTDCTSEGRR DNMKWCGTTQ 
NYDADQKFGF CPMAAHEEIC TTNEGVMYRI GDQWDKQHDM GHMMRCTCVG NGRGEWTCIA 
YSQLRDQCIV DDITYNVNDT FHKRHEEGHM LNCTCFGQGR GRWKCDPVDQ CQDSETGTFY 
QIGDSWEKYV HGVRYQCYCY GRGIGEWHCQ PLQTYPSSSG PVEVFITETP SQPNSHPIQW 
NAPQPSHISK YILRWRPKNS VGRWKEATIP GHLNSYTIKG LKPGVVYEGQ LISIQQYGHQ 
EVTRFDFTTT STSTPVTSNT VTGETTPFSP LVATSESVTE ITASSFVVSW VSASDTVSGF RVEYELSEEG 
DEPQYLDLPS TATSVNIPDL LPGRKYIVNV YQISEDGEQS LILSTSQTTA PDAPPDTTVD QVDDTSIVVR 
WSRPQAPITG YRIVYSPSVE GSSTELNLPE TANSVTLSDL QPGVQYNITI YAVEENQEST PVVIQQETTG 
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TPRSDTVPSP RDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VIPVNLPGEH GQRLPISRNT  
FAEVTGLSPG VTYYFKVFAV SHGRESKPLT AQQTTKLDAP TNLQFVNETD STVLVRWTPP 
RAQITGYRLT VGLTR  
 
FN3(Position: 291-1252 Predicted MW: 119KD): AAVYQPQPHP QPPPYGHCVT DSGVVYSVGM 
QWLKTQGNKQ MLCTCLGNGV SCQETAVTQT YGGNSNGEPC VLPFTYNGRT FYSCTTEGRQ 
DGHLWCSTTS NYEQDQKYSF CTDHTVLVQT RGGNSNGALC HFPFLYNNHN YTDCTSEGRR 
DNMKWCGTTQ NYDADQKFGF CPMAAHEEIC TTNEGVMYRI GDQWDKQHDM GHMMRCTCVG 
NGRGEWTCIA YSQLRDQCIV DDITYNVNDT FHKRHEEGHM LNCTCFGQGR GRWKCDPVDQ 
CQDSETGTFY QIGDSWEKYV HGVRYQCYCY GRGIGEWHCQ PLQTYPSSSG PVEVFITETP 
SQPNSHPIQW NAPQPSHISK YILRWRPKNS VGRWKEATIP GHLNSYTIKG LKPGVVYEGQ 
LISIQQYGHQ EVTRFDFTTT STSTPVTSNT VTGETTPFSP LVATSESVTE ITASSFVVSW VSASDTVSGF 
RVEYELSEEG DEPQYLDLPS TATSVNIPDL LPGRKYIVNV YQISEDGEQS LILSTSQTTA PDAPPDTTVD 
QVDDTSIVVR WSRPQAPITG YRIVYSPSVE GSSTELNLPE TANSVTLSDL QPGVQYNITI YAVEENQEST 
PVVIQQETTG TPRSDTVPSP RDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VIPVNLPGEH 
GQRLPISRNT  FAEVTGLSPG VTYYFKVFAV SHGRESKPLT AQQTTKLDAP TNLQFVNETD 
STVLVRWTPP RAQITGYRLT VGLTRRGQPR QYNVGPSVSK YPLRNLQPAS EYTVSLVAIK 
GNQESPKATG VFTTLQPGSS IPPYNTEVTE TTIVITWTPA PRIGFKLGVR PSQGGEAPRE VTSDSGSIVV 
SGLTPGVEYV YTIQVLRDGQ ERDAPIVNKV VTPLSPPTNL HLEANPDTGV LTVSWERSTT PDITGYRITT 
TPTNGQQGNS LEEVVHADQS SCTFDNLSPG LEYNVSVYTV KDDKE 
 
 
FN4(Position: 1506-2386 Predicted MW: 110KD): PGSK STATISGLKP GVDYTITVYA VTGRGDSPAS 
SKPISINYRT EIDKPSQMQV TDVQDNSISV KWLPSSSPVT GYRVTTTPKN GPGPTKTKTA GPDQTEMTIE 
GLQPTVEYVV SVYAQNPSGE SQPLVQTAVT NIDRPKGLAF TDVDVDSIKI AWESPQGQVS 
RYRVTYSSPE DGIHELFPAP DGEEDTAELQ GLRPGSEYTV SVVALHDDME SQPLIGTQST AIPAPTDLKF 
TQVTPTSLSA QWTPPNVQLT GYRVRVTPKE KTGPMKEINL APDSSSVVVS GLMVATKYEV 
SVYALKDTLT SRPAQGVVTT LENVSPPRRA RVTDATETTI TISWRTKTET ITGFQVDAVP ANGQTPIQRT 
IKPDVRSYTI TGLQPGTDYK IYLYTLNDNA RSSPVVIDAS TAIDAPSNLR FLATTPNSLL VSWQPPRARI 
TGYIIKYEKP GSPPREVVPR PRPGVTEATI TGLEPGTEYT IYVIALKNNQ KSEPLIGRKK TDELPQLVTL 
PHPNLHGPEI LDVPSTVQKT PFVTHPGYDT GNGIQLPGTS GQQPSVGQQM IFEEHGFRRT TPPTTATPIR 
HRPRPYPPNV GEEIQIGHIP REDVDYHLYP HGPGLNPNAS TGQEALSQTT ISWAPFQDTS EYIISCHPVG 
TDEEPLQFRV PGTSTSATLT GLTRGATYNV IVEALKDQQR HKVREEVVTV GNSVNEGLNQ 
PTDDSCFDPY TVSHYAVGDE WERMSESGFK LLCQCLGFGS GHFRCDSSRW CHDNGVNYKI 
GEKWDRQGEN GQMMSCTCLG NGKGEFKCDP HEATCYDDGK TYHVGEQWQK EYLGAICSCT 
CFGGQRGWRC DNCRRPGGEP SPEGTTGQSY NQYSQRYHQR TNTNVNCPIE CFMPLDVQAD REDSRE 
 
FN5(Position: 1656-2386 Predicted MW: 91KD): TDVDVDSIKI AWESPQGQVS RYRVTYSSPE DGIHELFPAP 
DGEEDTAELQ GLRPGSEYTV SVVALHDDME SQPLIGTQST AIPAPTDLKF TQVTPTSLSA 
QWTPPNVQLT GYRVRVTPKE KTGPMKEINL APDSSSVVVS GLMVATKYEV SVYALKDTLT 
SRPAQGVVTT LENVSPPRRA RVTDATETTI TISWRTKTET ITGFQVDAVP ANGQTPIQRT IKPDVRSYTI 
TGLQPGTDYK IYLYTLNDNA RSSPVVIDAS TAIDAPSNLR FLATTPNSLL VSWQPPRARI TGYIIKYEKP 
GSPPREVVPR PRPGVTEATI TGLEPGTEYT IYVIALKNNQ KSEPLIGRKK TDELPQLVTL PHPNLHGPEI 
LDVPSTVQKT PFVTHPGYDT GNGIQLPGTS GQQPSVGQQM IFEEHGFRRT TPPTTATPIR HRPRPYPPNV 
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GEEIQIGHIP REDVDYHLYP HGPGLNPNAS TGQEALSQTT ISWAPFQDTS EYIISCHPVG TDEEPLQFRV 
PGTSTSATLT GLTRGATYNV IVEALKDQQR HKVREEVVTV GNSVNEGLNQ PTDDSCFDPY 
TVSHYAVGDE WERMSESGFK LLCQCLGFGS GHFRCDSSRW CHDNGVNYKI GEKWDRQGEN 
GQMMSCTCLG NGKGEFKCDP HEATCYDDGK TYHVGEQWQK EYLGAICSCT CFGGQRGWRC 
DNCRRPGGEP SPEGTTGQSY NQYSQRYHQR TNTNVNCPIE CFMPLDVQAD REDSRE 
 
FN6(Position: 1285-1575 Predicted MW: 38KD): RVTWAPP PSIDLTNFLV RYSPVKNEED VAELSISPSD 
NAVVLTNLLP GTEYVVSVSS VYEQHESTPL RGRQKTGLDS PTGIDFSDIT ANSFTVHWIA PRATITGYRI 
RHHPEHFSGR PREDRVPHSR NSITLTNLTP GTEYVVSIVA LNGREESPLL IGQQSTVSDV PRDLEVVAAT 
PTSLLISWDA PAVTVRYYRI TYGETGGNSP VQEFTVPGSK STATISGLKP GVDYTITVYA VTGRGDSPAS 
SKPISINYRT EIDKPSQMQV TDVQDNSISV KWLPSSSPVT GYR 
 
FN7(Position: 1940-2180 Predicted MW: 31KD): TGYIIKYEKP GSPPREVVPR PRPGVTEATI TGLEPGTEYT 
IYVIALKNNQ KSEPLIGRKK TDELPQLVTL PHPNLHGPEI LDVPSTVQKT PFVTHPGYDT GNGIQLPGTS 
GQQPSVGQQM IFEEHGFRRT TPPTTATPIR HRPRPYPPNV GEEIQIGHIP REDVDYHLYP HGPGLNPNAS 
TGQEALSQTT ISWAPFQDTS EYIISCHPVG TDEEPLQFRV PGTSTSATLT GLTRGATYNV 
 
FN8(Position:  881-1073 Predicted MW: 22.4KD): YAVEENQEST PVVIQQETTG TPRSDTVPSP 
RDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VIPVNLPGEH GQRLPISRNT FAEVTGLSPG 
VTYYFKVFAV SHGRESKPLT AQQTTKLDAP 
 
FN9(Position: 0-109 Predicted MW: 12KD): MLRGPGPGLL LLAVQCLGTA VPSTGASKSK RQAQQMVQPQ 
SPVAVSQSKP GCYDNGKHYQ INQQWERTYL GNALVCTCYG GSRGFNCESK PEAEETCFDK 
YTGNTYRVGD TYERPK 
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